Akebia Therapeutics, Inc. AKBA 深 沪
等待开盘 02-06 09:30:00 美东时间
1.38
+0.010
+0.73%
华盛通- 最 高1.39
- 今 开1.36
- 成交量 327.16万股
- 最 低 1.35
- 昨 收 1.37
- 总市值 3.66亿
- 52周最高 4.0787
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 1.30
- 委 比 23.09%
- 总股本 2.65亿
- 历史最高 31.00
- 量 比 1.23
- 振 幅 2.92%
- 历史最低 0.241
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akebia Therapeutics Grants Stock Options to New Employees
Akebia Therapeutics Grants Stock Options to New Employees Akebia Therapeutics Inc. has granted two newly-hired employees options to purchase a total of 132,675 shares of its common stock at an exercise price of $1.41 per share, matching the closing price on the grant date of January 30, 2026. The st
02-03 05:06
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Akebia Therapeutics granted 132,675 stock options to two new employees on January 30, 2026. The options have an exercise price of $1.41 per share, vesting over four years with 25% after one year and quarterly thereafter. The options are part of the company's inducement award program and stock option agreement. Akebia Therapeutics, based in Cambridge, Massachusetts, focuses on improving lives affected by kidney disease. For more info, contact M...
02-02 21:05
Akebia Therapeutics Updates Executive Severance and Leadership Terms
Akebia Therapeutics ( ($AKBA) ) has provided an announcement. On January 27, 20...
01-30 21:59
Akebia Therapeutics Doses First Participant In Phase 2 Clinical Study Of Praliciguat To Treat Biopsy-Confirmed Focal Segmental Glomerulosclerosis
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in a Phase 2
01-06 21:03
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Akebia Therapeutics announced the initiation of a Phase 2 clinical trial for praliciguat, targeting biopsy-confirmed FSGS, a rare kidney disease without approved treatments. The trial aims to assess praliciguat's efficacy and safety in reducing kidney failure risk through changes in urine protein-to-creatinine ratio. Approximately 60 patients will receive either praliciguat or placebo for 24 weeks, followed by an additional 24 weeks of open-label...
01-06 13:00
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Cambridge, MA (January 5, 2026) - Akebia Therapeutics, Inc., a biopharmaceutical company focused on improving lives impacted by kidney disease, granted a newly hired employee options to purchase 197,900 shares of its common stock on December 31, 2025. The options were granted as an inducement for the employee to join Akebia and comply with Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.61 per share, equal to the closing price on the ...
01-05 21:05
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $5 price target.
2025-12-02 23:45
Cyclerion Receives Milestone Payment from Akebia
Cyclerion Therapeutics ( ($CYCN) ) has issued an update. On December 1, 2025, A...
2025-12-02 06:28
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.
2025-12-01 22:43
